Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Anti-JNK2 Antibody (8A226)

😃Good
Catalog No. TMAY-01114
Alias SAPK1a, SAPK, PRKM9, p54aSAPK, p54a, mitogen-activated protein kinase 9, JNK-55, JNK2β, JNK2α, JNK2BETA, JNK2B, JNK2ALPHA, JNK2A, JNK2

Anti-JNK2 Antibody (8A226) is a Mouse antibody targeting JNK2. Anti-JNK2 Antibody (8A226) can be used in WB,ELISA,IP.

Anti-JNK2 Antibody (8A226)

Anti-JNK2 Antibody (8A226)

😃Good
Catalog No. TMAY-01114Alias SAPK1a, SAPK, PRKM9, p54aSAPK, p54a, mitogen-activated protein kinase 9, JNK-55, JNK2β, JNK2α, JNK2BETA, JNK2B, JNK2ALPHA, JNK2A, JNK2
Anti-JNK2 Antibody (8A226) is a Mouse antibody targeting JNK2. Anti-JNK2 Antibody (8A226) can be used in WB,ELISA,IP.
Pack SizePriceAvailabilityQuantity
100 μL$198 7-10 days
Bulk & Custom
Add to Cart
Questions
View More
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Anti-JNK2 Antibody (8A226) is a Mouse antibody targeting JNK2. Anti-JNK2 Antibody (8A226) can be used in WB,ELISA,IP.
AliasSAPK1a, SAPK, PRKM9, p54aSAPK, p54a, mitogen-activated protein kinase 9, JNK-55, JNK2β, JNK2α, JNK2BETA, JNK2B, JNK2ALPHA, JNK2A, JNK2
Ig Type
Monoclonal Mouse IgG2b
Clone
8A226
Reactivity
Human
Verified Activity
1. Anti-MAPK9 mouse monoclonal antibody at 1:500 dilution.

-Lane A: HEPG2 Whole Cell Lysate.

-Lane B: A549 Whole Cell Lysate.

-Lane C: Jurkat Whole Cell lysate.

-Lysates/proteins at 30 μg per lane.

-Secondary

-Rabbit Anti-Mouse IgG F(ab)2/HRP at 1/10000 dilution.

-Developed using the ECL technique.

-Performed under reducing conditions.

-Predicted band size:48 kDa.

-Observed band size:52 kDa(We are unsure as to the identity of these extra bands.)

2. MAPK9 was immunoprecipitated using:

-Lane A:0.5 mg HepG2 Whole Cell Lysate.

-Lane B:0.5 mg Hela Whole Cell Lysate.

-Lane C:0.5 mg Jurkat Whole Cell Lysate.

-Lane D:0.5 mg MCF-7 Whole Cell Lysate

-0.5 µL anti-MAPK9 mouse monoclonal antibody and 15 μl of 50 % Protein G agarose.

-Primary antibody:

-Anti-MAPK9 mouse monoclonal antibody, at 1:500 dilution.

-Secondary antibody:

-Dylight 800-labeled antibody to Mouse IgG (H+L), at 1:7500 dilution.

-Developed using the odyssey technique.

-Performed under reducing conditions.

-Predicted band size: 44 kDa.

-Observed band size: 44 kDa
Application
WB,ELISA,IP
Recommended Dose
WB: 1:500-1:1000; ELISA: 1:5000-1:10000; IP: 1-2 μL/mg of lysate
Antibody Type
Monoclonal
Host SpeciesMouse
ConstructionThis antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human MAPK9 (rh MAPK9; TMPY-04550; NP_002743.3; Met 1-Arg 424). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
PurificationProtein A
AppearanceLiquid
Formulation0.2 μm filtered solution in PBS
Research BackgroundMitogen-activated protein kinase 9 (MAPK9), also well known as c-Jun N-terminal kinase (JNK2), is a member of the MAP kinase subfamily belonging to the protein kinase superfamily. MAPK9 responds to activation by environmental stress and pro-inflammatory cytokines by phosphorylating some transcription factors, such as c-Jun and ATF2. The crystal structure of human JNK2 complexed with an indazole inhibitor by applying a high-throughput protein engineering and surface-site mutagenesis approach. A novel conformation of the activation loop is observed, which is not compatible with its phosphorylation by upstream kinases. This activation inhibitory conformation of JNK2 is stabilized by the MAP kinase insert that interacts with the activation loop in an induced-fit manner. It suggests that the MAP kinase insert of JNK2 plays a role in the regulation of JNK2 activation, possibly by interacting with intracellular binding partners. JNK2 deficiency leads to reduced c-Jun degradation, thereby augmenting c-Jun levels and cellular proliferation, and suggests that JNK2 is a negative regulator of cellular proliferation in multiple cell types. JNK2 prevents replicative stress by coordinating cell cycle progression and DNA damage repair mechanisms. JNK2 blocks the ubiquitination of tumor suppressor p53, and thus increases the stability of p53 in nonstressed cells. JNK2 negatively regulates antigen-specific CD8+ T cell expansion and effector function, and thus selectively blocking JNK2 in CD8+ T cells may potentially enhance the anti-tumor immune response. Lack of JNK2 expression was associated with higher tumor aneuploidy and reduced DNA damage response. Additionally, the JNK2 protein could be a novel therapeutic target in dry eye disease and may provide a novel target for the prevention of vascular disease and atherosclerosis.
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Immunogen
Recombinant Human JNK2 proteimn (TMPY-04550)
Antigen Species
Human
Chemical Properties
Stability & Storage
Stability & StorageStore at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free.
TransportShipping with blue ice.

Sci Citations

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Anti-JNK2 Antibody (8A226) | purchase Anti-JNK2 Antibody (8A226) | Anti-JNK2 Antibody (8A226) cost | order Anti-JNK2 Antibody (8A226)